Literature DB >> 199350

Intracerebral delayed hypersensitivity reactions in glioblastoma multiforme patients.

L Albright, J A Seab, A K Ommaya.   

Abstract

Patients with malignant gliomas who had undergone BCG inoculation were injected intratumorally with PPD to induce an intratumoral delayed hypersensitivity reaction. Histopathological examination of the tumor before and after PPD injections revealed that chronic inflammatory responses were increased after injection in four of the five patients. In no case, however, was the response more than moderate, and in no case did the inflammatory response encompass the tumor at its peripheral margins. Intracerebral delayed hypersensitivity reactions were evoked in humans with acceptable morbidity. The mild reactions evoked did not cause detectable tumor regression.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 199350     DOI: 10.1002/1097-0142(197703)39:3<1331::aid-cncr2820390348>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 2.  Glioblastoma multiforme: morphology and biology.

Authors:  K Jellinger
Journal:  Acta Neurochir (Wien)       Date:  1978       Impact factor: 2.216

Review 3.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

Review 4.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Authors:  Amy B Heimberger; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

5.  A study of reactions to Corynebacterium parvum (C. parvum) in the brain and dermis of the rat.

Authors:  H M Cravioto; G M Hochwald; J Ransohoff
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

Review 6.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

7.  Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains.

Authors:  Tanya Dutta; Alexander Spence; Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 8.  Immunotherapy of brain cancers: the past, the present, and future directions.

Authors:  Lisheng Ge; Neil Hoa; Daniela A Bota; Josephine Natividad; Andrew Howat; Martin R Jadus
Journal:  Clin Dev Immunol       Date:  2011-03-08

9.  A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.

Authors:  D E Bullard; D G Thomas; J L Darling; C J Wikstrand; J V Diengdoh; R O Barnard; J G Bodmer; D D Bigner
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.